clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Uveitis, Anterior D014606 11 associated lipids
Whooping Cough D014917 6 associated lipids
Wound Infection D014946 12 associated lipids
Sexually Transmitted Diseases, Bacterial D015231 5 associated lipids
Mycobacterium avium-intracellulare Infection D015270 4 associated lipids
Discitis D015299 2 associated lipids
Leprosy, Borderline D015439 3 associated lipids
Leprosy, Lepromatous D015440 2 associated lipids
Eye Injuries, Penetrating D015807 2 associated lipids
Eye Infections D015817 1 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Mosdósi B et al. Severe acrocyanosis precipitated by cold agglutinin secondary to infection with Mycoplasma pneumoniae in a pediatric patient. 2017 Croat. Med. J. pmid:29308834
Zhang X and Hu C Selecting optimal columns for clarithromycin impurity analysis according to the quantitative relationship of hydrophobic subtraction model. 2017 J Pharm Biomed Anal pmid:28024686
Addo KK et al. Genotyping and drug susceptibility testing of mycobacterial isolates from population-based tuberculosis prevalence survey in Ghana. 2017 BMC Infect. Dis. pmid:29197331
Liu W et al. Rapid detection of mutations in erm(41) and rrl associated with clarithromycin resistance in Mycobacterium abscessus complex by denaturing gradient gel electrophoresis. 2017 J. Microbiol. Methods pmid:29079298
Koh WJ et al. Mycobacterial Characteristics and Treatment Outcomes in Mycobacterium abscessus Lung Disease. 2017 Clin. Infect. Dis. pmid:28011608
Chang CH et al. Non-Tuberculous Mycobacteria Infection Following Autologous Fat Grafting on the Face. 2017 Aesthet Surg J pmid:29045552
Çekin AH et al. Use of probiotics as an adjuvant to sequential H. pylori eradication therapy: impact on eradication rates, treatment resistance, treatment-related side effects, and patient compliance. 2017 Turk J Gastroenterol pmid:28007678
Ikeue T et al. Pleuritis Caused by Mycobacterium kyorinense without Pulmonary Involvement. 2017 Intern. Med. pmid:28924121
Panozzo C et al. Chemicals or mutations that target mitochondrial translation can rescue the respiratory deficiency of yeast bcs1 mutants. 2017 Biochim. Biophys. Acta pmid:28888990
Geng X et al. The Bifunctional Enzyme SpoT Is Involved in the Clarithromycin Tolerance of Helicobacter pylori by Upregulating the Transporters HP0939, HP1017, HP0497, and HP0471. 2017 Antimicrob. Agents Chemother. pmid:28242673
Emmanuel R et al. Antimicrobial efficacy of drug blended biosynthesized colloidal gold nanoparticles from Justicia glauca against oral pathogens: A nanoantibiotic approach. 2017 Microb. Pathog. pmid:29101061
Larsen EL et al. Clarithromycin, trimethoprim, and penicillin and oxidative nucleic acid modifications in humans: randomised, controlled trials. 2017 Br J Clin Pharmacol pmid:28185274
Ono S et al. Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin. 2017 Helicobacter pmid:28098408
Gouin-Thibault I et al. Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin. 2017 J. Thromb. Haemost. pmid:27893182
Park J et al. Progression and Treatment Outcomes of Lung Disease Caused by Mycobacterium abscessus and Mycobacterium massiliense. 2017 Clin. Infect. Dis. pmid:28011609
Park SM et al. Randomized clinical trial comparing 10- or 14-day sequential therapy and 10- or 14-day concomitant therapy for the first line empirical treatment of Helicobacter pylori infection. 2017 J. Gastroenterol. Hepatol. pmid:27505301
Ishiguro N et al. Therapeutic efficacy of azithromycin, clarithromycin, minocycline and tosufloxacin against macrolide-resistant and macrolide-sensitive Mycoplasma pneumoniae pneumonia in pediatric patients. 2017 PLoS ONE pmid:28288170
Attaran B et al. Effect of biofilm formation by clinical isolates of on the efflux-mediated resistance to commonly used antibiotics. 2017 World J. Gastroenterol. pmid:28275296
Osaki T et al. Usefulness of detection of clarithromycin-resistant Helicobacter pylori from fecal specimens for young adults treated with eradication therapy. 2017 Helicobacter pmid:28544222
Chang CT et al. Antibiotic treatment of zebrafish mycobacteriosis: tolerance and efficacy of treatments with tigecycline and clarithromycin. 2017 J. Fish Dis. pmid:28422304
Furuya H et al. SAPHO syndrome-like presentation of disseminated nontuberculous mycobacterial infection in a case with neutralizing anti-IFNγ autoantibody. 2017 Rheumatology (Oxford) pmid:28371927
Ye JF et al. Evaluation of first-line bismuth-containing 7-day concomitant quintuple therapy for Helicobacter pylori eradication. 2017 J Dig Dis pmid:29119724
Chang KH et al. Comparison of antibiotic regimens in preterm premature rupture of membranes: neonatal morbidity and 2-year follow-up of neurologic outcome. 2017 J. Matern. Fetal. Neonatal. Med. pmid:27687157
Sotto RB et al. Sub-lethal pharmaceutical hazard tracking in adult zebrafish using untargeted LC-MS environmental metabolomics. 2017 J. Hazard. Mater. pmid:28623724
Liatsos C and Leontiadis GII The "report card" to grade H. Pylori treatment regimens: is it achievable in real-world in areas with high clarithromycin resistance? 2017 J Gastrointestin Liver Dis pmid:28617893
Chew CA et al. The diagnosis and management of H. pylori infection in Singapore. 2017 Singapore Med J pmid:28536725
Gunnarsdottir AI et al. Antibiotic susceptibility of Helicobacter pylori in Iceland. 2017 Infect Dis (Lond) pmid:28440099
Carneiro MDS et al. Lack of association between rrl and erm(41) mutations and clarithromycin resistance in Mycobacterium abscessus complex. 2017 Mem. Inst. Oswaldo Cruz pmid:29091138
Oikawa R et al. Enrichment of Helicobacter pylori mutant strains after eradication therapy analyzed by gastric wash-based quantitative pyrosequencing. 2017 Tumour Biol. pmid:28990461
Radzikowska E et al. Cryptogenic organizing pneumonia-Results of treatment with clarithromycin versus corticosteroids-Observational study. 2017 PLoS ONE pmid:28945804
Chew KL et al. Predominance of clarithromycin-susceptible Mycobacterium massiliense subspecies: Characterization of the Mycobacterium abscessus complex at a tertiary acute care hospital. 2017 J. Med. Microbiol. pmid:28874233
Mougari F et al. Evaluation of the new GenoType NTM-DR kit for the molecular detection of antimicrobial resistance in non-tuberculous mycobacteria. 2017 J. Antimicrob. Chemother. pmid:28333340
Anwar HF et al. Synthesis of clarithromycin ketolides chemically modified at the unreactive C10-methyl group. 2017 Bioorg. Med. Chem. pmid:28302508
Turvey SL et al. Mycobacterium branderi infection: Case report and literature review of an unusual and difficult-to-treat non-tuberculous mycobacterium. 2017 Int. J. Infect. Dis. pmid:28268125
Kadota JI et al. The clinical efficacy of a clarithromycin-based regimen for Mycobacterium avium complex disease: A nationwide post-marketing study. 2017 J. Infect. Chemother. pmid:28254517
Quinn KL et al. Macrolides, Digoxin Toxicity and the Risk of Sudden Death: A Population-Based Study. 2017 Drug Saf pmid:28421551
Gonzalez-Hormazabal P et al. Prevalence of clarithromycin resistance in Helicobacter pylori in Santiago, Chile, estimated by real-time PCR directly from gastric mucosa. 2018 BMC Gastroenterol pmid:29925321
Clarithromycin in patients with coronary artery disease. 2018 Med Lett Drugs Ther pmid:29913468
Li M et al. Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori. 2018 Helicobacter pmid:29873436
Blümel B et al. Retrospective study on outcome of salvage Helicobacter pylori eradication therapies based on molecular genetic susceptibility testing. 2018 Helicobacter pmid:29873430
Tsutsui A et al. Trends and patterns of national antimicrobial consumption in Japan from 2004 to 2016. 2018 J. Infect. Chemother. pmid:29428566
Tarhini M et al. First-line treatment of Helicobacter pylori in Lebanon: Comparison of bismuth-containing quadruple therapy versus 14-days sequential therapy. 2018 Microb. Pathog. pmid:29428426
Kobayashi T et al. The potential role of clarithromycin addition to lenalidomide and dexamethasone therapy (BiRd) in multiple myeloma. 2018 Ann. Hematol. pmid:29427183
Wang S et al. Enhanced adsorption of ionizable antibiotics on activated carbon fiber under electrochemical assistance in continuous-flow modes. 2018 Water Res. pmid:29426033
Yagbasan A et al. A Prospective, randomized study comparing 7-day and 14-day quadruple therapies as first-line treatments for helicobacter pylori infection in patients with functional dyspepsia. 2018 Niger J Clin Pract pmid:29411724
Ersoy B et al. The anti-inflammatory effects of erythromycin, clarithromycin, azithromycin and roxithromycin on histamine-induced otitis media with effusion in guinea pigs. 2018 J Laryngol Otol pmid:29888693
Inagaki Y et al. Disseminated Cutaneous Infection of Mycobacterium colombiense in a Patient with Myelodysplastic Syndrome. 2018 Intern. Med. pmid:29093379
De Francesco V et al. Quadruple, sequential, and concomitant first-line therapies for H. pylori eradication: a prospective, randomized study. 2018 Dig Liver Dis pmid:29089267
Cerqueira RM et al. Cumulative Helicobacter Pylori Eradication Rates by Adopting First- and Second- Line Regimens Proposed by the Maastricht IV Consensus in Obese Patients Undergoing Gastric Bypass Surgery. 2018 Obes Surg pmid:29076008
Sancak S et al. A pioneering study: oral clarithromycin treatment for feeding intolerance in very low birth weight preterm infants. 2018 J. Matern. Fetal. Neonatal. Med. pmid:28279123